ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
ImageneBio, Inc. (IMA) - Net Assets
Latest net assets as of September 2025: $139.83 Million USD
Based on the latest financial reports, ImageneBio, Inc. (IMA) has net assets worth $139.83 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($160.88 Million) and total liabilities ($21.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $139.83 Million |
| % of Total Assets | 86.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.35 |
ImageneBio, Inc. - Net Assets Trend (2018–2024)
This chart illustrates how ImageneBio, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ImageneBio, Inc. (2018–2024)
The table below shows the annual net assets of ImageneBio, Inc. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $125.93 Million | -25.82% |
| 2023-12-31 | $169.76 Million | +15.51% |
| 2022-12-31 | $146.97 Million | -29.30% |
| 2021-12-31 | $207.88 Million | +305.72% |
| 2020-12-31 | $-101.05 Million | -64.40% |
| 2019-12-31 | $-61.46 Million | -34.08% |
| 2018-12-31 | $-45.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ImageneBio, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28135300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | 0.04% |
| Other Comprehensive Income | $68.00K | 0.05% |
| Other Components | $457.44 Million | 363.24% |
| Total Equity | $125.93 Million | 100.00% |
ImageneBio, Inc. Competitors by Market Cap
The table below lists competitors of ImageneBio, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
T.K.S. Technologies Public Company Limited
BK:TKS
|
$50.05 Million |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
$50.06 Million |
|
Tembo Global Industries Limited
NSE:TEMBO
|
$50.06 Million |
|
Saksiam Leasing Public Company Limited
BK:SAK
|
$50.08 Million |
|
Cameo Communications Inc
TW:6142
|
$50.00 Million |
|
ReaLy Development & Construction
TWO:2596
|
$50.00 Million |
|
SOLTEC POWER HOLD. EO-25
F:5PZ
|
$49.99 Million |
|
Marie Brizard Wine & Spirits
PA:MBWS
|
$49.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ImageneBio, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 169,757,000 to 125,934,000, a change of -43,823,000 (-25.8%).
- Net loss of 36,568,000 reduced equity.
- Other comprehensive income increased equity by 116,000.
- Other factors decreased equity by 7,371,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.57 Million | -29.04% |
| Other Comprehensive Income | $116.00K | +0.09% |
| Other Changes | $-7.37 Million | -5.85% |
| Total Change | $- | -25.82% |
Book Value vs Market Value Analysis
This analysis compares ImageneBio, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.31x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-1.28 | $6.02 | x |
| 2019-12-31 | $-1.71 | $6.02 | x |
| 2020-12-31 | $-7.22 | $6.02 | x |
| 2021-12-31 | $5.78 | $6.02 | x |
| 2022-12-31 | $4.06 | $6.02 | x |
| 2023-12-31 | $4.07 | $6.02 | x |
| 2024-12-31 | $2.61 | $6.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ImageneBio, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1044.80%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.12x
- Recent ROE (-29.04%) is below the historical average (-18.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -4127.78% | 0.05x | 0.00x | $-36.28 Million |
| 2019 | 0.00% | -122.28% | 0.16x | 0.00x | $-10.67 Million |
| 2020 | 0.00% | -481.36% | 0.05x | 0.00x | $-34.15 Million |
| 2021 | -16.41% | -110.10% | 0.13x | 1.19x | $-54.90 Million |
| 2022 | -46.79% | -440.29% | 0.09x | 1.17x | $-83.46 Million |
| 2023 | -40.16% | -744.17% | 0.05x | 1.13x | $-85.14 Million |
| 2024 | -29.04% | -1044.80% | 0.02x | 1.12x | $-49.16 Million |
Industry Comparison
This section compares ImageneBio, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ImageneBio, Inc. (IMA) | $139.83 Million | 0.00% | 0.15x | $50.02 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |